Back to search
FDAFDA · Food and drugs·Recall number D-0329-2019

Valsartan and Hydrochlorothiazide Tablets, USP 160/12.5 mg, (a) 90-count bottle (NDC 0378-6322-77), (b) 500-count bottles (NDC 0378-6322-05), Rx Only, Made in India, Manufactured for: Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 U.S.A.

Published December 19, 2018 · Recall initiated: December 4, 2018

Summary

FDA records drug Class II recall D-0329-2019, published December 19, 2018 and initiated December 4, 2018. Recalling firm: Mylan Laboratories Limited, (Nashik FDF); Status: Ongoing; Reported quantity: 50,595 HDPE bottles; Lot: Lot numbers: 2008880 3084358 3084359 3093801 3084359 3084361 3093801. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.

What to do

Voluntary: Firm initiated · Press Release

Get an email if VALSARTAN AND HYDROCHLOROTHIAZIDE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
VALSARTAN AND HYDROCHLOROTHIAZIDE
Manufacturer
Mylan Laboratories Limited, (Nashik FDF)
Distributor
Product was distributed throughout the United States to several major distributors, including Puerto Rico.
UPC
0303786323777
Lot
Lot numbers: 2008880 3084358 3084359 3093801 3084359 3084361 3093801
Risk classification
Class II
Area (FDA)
drug
Country
India

Related recalls

Questions about this recall

Was Valsartan and Hydrochlorothiazide Tablets, USP 160/12.5 mg, (a) 90-count bottle (NDC 0378-6322-77), (b) 500-count bottles (NDC 0378-6322-05), Rx Only, Made in India, Manufactured for: Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 U.S.A. recalled?

Yes. FDA published recall D-0329-2019 on December 19, 2018. Reported hazard: GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.

What should I do if I have this product?

Voluntary: Firm initiated · Press Release

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: VALSARTAN AND HYDROCHLOROTHIAZIDE. UPC: 0303786323777.